Screener
Altimmune ALT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Altimmune’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326190-26-000040
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $97,601 | $43,760 |
| Restricted cash | 42 | 42 |
| Total cash, cash equivalents and restricted cash | 97,643 | 43,802 |
| Short-term investments | 233,939 | 229,696 |
| Accounts and other receivables | 1,665 | 1,219 |
| Income tax and R&D incentive receivables | — | 518 |
| Prepaid expenses and other current assets | 1,429 | 2,957 |
Item 1. Financial Statements
FAQ
- What is Altimmune's cash & equivalents?
- Altimmune (ALT) reported cash & equivalents of $97.64M in Q1 2026.
- How has Altimmune's cash & equivalents changed year-over-year?
- Altimmune's cash & equivalents increased by 98.7% year-over-year, from $49.15M to $97.64M.
- What is the long-term trend for Altimmune's cash & equivalents?
- Over 5 years (2020 to 2025), Altimmune's cash & equivalents has grown at a -17.7% compound annual growth rate (CAGR), from $115.95M to $43.8M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Altimmune's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude